Researchers are making much-needed progress in developing treatments for patients with three rare malignancies: recurrent and refractory primary central nervous (CNS) system lymphoma, secondary CNS lymphoma, and primary vitreoretinal lymphoma.
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.
A molecular signature for aggressive-variant prostate carcinoma can predict which men with castration-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin.
Adding daratumumab to standard of care is a feasible alternative to autologous stem cell transplantation with standard regimens in multiple myeloma patients.
Atezolizumab treatment beyond progression might benefit patients with advanced non–small-cell lung cancer, according to the first report from the randomized phase III OAK trial.
Lorlatinib exhibits durable responses in patients with ALK-positive non–small-cell lung cancer and robust intracranial activity in those with brain metastases.
Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma.
Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.
Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients.
The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer.